B · Normal
[ST Wanbang: Methylcobalamin receives EU orphan drug designation] On November 17, ST Wanbang (002082.SZ) announced that methylcobalamin independently developed by the company's wholly-owned subsidiary Wanbangdang Pharmaceutical has received orphan drug designation from the European Commission for the treatment of amyotrophic lateral sclerosis (ALS). The drug has previously been designated as an orphan drug by the U.S. FDA. Methylcobalamin freeze-dried powder injection has been approved for ALS treatment in Japan in September 2024. No similar product has been approved in the EU. This certification will accelerate the company's strategic layout of pharmaceutical internationalization, and the products will enjoy 10 years of market exclusivity and other incentive policies after being launched in the EU.
Comments